bemcentinib, also known as bgb324 or r428, is an experimental oral small molecule that is an inhibitor of axl kinase. bemcentinib was licensed from rigel pharmaceuticals by bergenbio and currently undergoing six phase ii trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics.